<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00890500</url>
  </required_header>
  <id_info>
    <org_study_id>FT1050-01</org_study_id>
    <nct_id>NCT00890500</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.</brief_title>
  <official_title>A Phase I Study of Reduced Intensity, Sequential Double Umbilical Cord Blood Transplantation Using ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematological Malignancies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fate Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fate Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine the safety and efficacy of a reduced
      intensity conditioning regimen during a double umbilical cord blood unit transplant with one
      of the cord blood units modulated with ProHema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this research study is to determine the safety and efficacy of a reduced
      intensity conditioning regimen during a double umbilical cord blood unit transplant with one
      of the cord blood units modulated with ProHema.

      -As part of this research study cord units will be modulated in the laboratory with ProHema
      before it is given to the participant. Two different treatment groups will be tested. Group
      1: will have the second cord blood unit modulated with ProHema; Group 2: will have the first
      cord blood unit modulated with ProHema.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the safety of ProHema modulated umbilical cord blood units when used for transplantation in a reduced intensity, sequential umbilical cord blood transplantation model.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to engraftment of umbilical cord blood units</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional chimerism of transplanted cord blood units</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of acute and chronic GVHD</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30- and 100-day treatment related mortality</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of immune reconstitution and relapse-free and overall survival at 1 and 2 years after transplantation</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hematologic Malignancies</condition>
  <condition>Allogeneic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 umbilical cord units: Second cord blood unit modulated with ProHema</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 umbilical cord units: First cord blood unit modulated with ProHema</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30mg/m2/day IV x 6 days</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>100 mg/m2/day IV x 1 day</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antithymocyte Globulin</intervention_name>
    <description>1mg/kg/day x 4 days</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>GVHD Prophylaxis: Target range 3-12 ng/ml</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>GVHD Prophylaxis: Target range 5-10 ng/ml</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hematologic malignancies for whom allogeneic stem cell transplantation
             is deemed clinically appropriate

          -  Patient must be ineligible for traditional myeloablative transplantation according to
             treating physician

          -  Lack of 6/6 or 5/6 HLA-matched related, 8/8 HLA-matched unrelated donor, or unrelated
             donor not available within a time frame necessary to perform a potentially curative
             stem cell transplant

          -  18-65 years of age

          -  ECOG Performance Status 0-2

        Exclusion Criteria:

          -  The following hematologic malignancies are excluded:

               -  Myelofibrosis unless there has been exposure to cytotoxic chemotherapy for the
                  treatment of progression to acute myeloid leukemia

               -  Chronic Myelogenous Leukemia, unless there has been exposure to cytotoxic
                  chemotherapy for the treatment of blast phase, 3) Aplastic anemia, in the absence
                  of transformation to Myelodysplastic disorder

          -  Cardiac disease: symptomatic congestive heart failure or evidence of left ventricular
             dysfunction as measured by gated radionucleotide ventriculogram or echocardiogram;
             active angina pectoris, or uncontrolled hypertension

          -  Pulmonary disease: symptomatic chronic obstructive lung disease, symptomatic
             restrictive lung disease, or corrected DLCO of &lt; 50% of predicted, corrected
             hemoglobin

          -  Renal disease: serum creatinine &gt; 2.0mg/dl

          -  Hepatic disease: serum bilirubin &gt; 2.0mg/dl (expect in the case of Gilbert's syndrome
             or ongoing hemolytic anemia), SGOT or SGPT &gt; 3 x upper limit of normal

          -  Neurologic disease: symptomatic leukoencephalopathy, active CNS malignancy or other
             neuropsychiatric abnormalities believed to preclude transplantation

          -  HIV antibody

          -  Uncontrolled infection

          -  Pregnancy or breast feeding mother

          -  Inability to comply with the requirements for care after allogeneic stem cell
             transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corey Cutler, MD, MPH, FRCP(C)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2009</study_first_submitted>
  <study_first_submitted_qc>April 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2009</study_first_posted>
  <last_update_submitted>October 7, 2013</last_update_submitted>
  <last_update_submitted_qc>October 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

